Role of CD14 in responses to clinical isolates of Escherichia coli: effects of K1 capsule expression.

Department of Microbiology and Immunology, CUNY Medical School, and Sophie Davis School for Biomedical Sciences, City College of New York, New York, New York, USA.
Infection and Immunity (Impact Factor: 4.16). 12/2007; 75(11):5415-24. DOI: 10.1128/IAI.00601-07
Source: PubMed

ABSTRACT Severe bacterial infections leading to sepsis or septic shock can be induced by bacteria that utilize different factors to drive pathogenicity and/or virulence, leading to disease in the host. One major factor expressed by all clinical isolates of gram-negative bacteria is lipopolysaccharide (LPS); a second factor expressed by some Escherichia coli strains is a K1 polysaccharide capsule. To determine the role of the CD14 LPS receptor in the pathogenic effects of naturally occurring E. coli, the responses of CD14-/- and CD14+/+ mice to three different isolates of E. coli obtained from sepsis patients were compared; two isolates express both smooth LPS and the K1 antigen, while the third isolate expresses only LPS and is negative for K1. An additional K1-positive isolate obtained from a newborn with meningitis and a K1-negative isogenic mutant of this strain were also used for these studies. CD14-/- mice were resistant to the lethal effects of the K1-negative isolates. This resistance was accompanied by significantly lower levels of systemic tumor necrosis factor alpha (TNF-alpha) and interleukin-6 (IL-6) in these mice than in CD14+/+ mice, enhanced clearance of the bacteria, and significantly fewer additional gross symptoms. In contrast, CD14-/- mice were as sensitive as CD14+/+ mice to the lethal effects of the K1-positive isolates, even though they had significantly lower levels of TNF-alpha and IL-6 than CD14+/+ mice. These studies show that different bacterial isolates can use distinctly different mechanisms to cause disease and suggest that new, nonantibiotic therapeutics need to be directed against multiple targets.

  • European Urology Supplements; 03/2011
  • [Show abstract] [Hide abstract]
    ABSTRACT: Embryonic stem (ES) cells are a powerful model for the development of cells responsible for cellular immune response. Therefore we analyzed the defense- and phagocytic capacity of Embryoid Bodies (EBs) derived from ES cells using in vitro inflammatory conditions caused by Escherichia coli (E. coli). Further we used this phagocytic activity to purify activated immune cells. Our data show that spontaneously differentiated 18-day-old EBs of the cell line CGR8 contained immune cells which were positive for CD45, CD68, CD11b, F4/80 and CD19. Exposure of these EBs to E. coli with defined infection doses of bacterial colony forming units (CFUs) led to a significant time-dependent reduction of CFUs, indicating immune responses exerted by EBs. This was paralleled by an up-regulation of inflammatory cytokines, i.e. IL-1β and TNF-α. Western Blot analysis of infected EBs indicated an up-regulation of CD14 and cytochrome b-245 heavy chain (NOX2). Silencing of NOX2 significantly reduced the antibacterial capacity of EBs which was partially explained by reduction of F4/80 positive cells. To identify, isolate and further cultivate phagocytic active cells from differentiated EBs, a co-cultivation assay of differentiated ES cells with green fluorescent protein (GFP)-labeled E. coli was established. Co-localization of GFP-labeled E. coli with cells positive for CD45, CD68 and F4/80 revealed time-dependent phagocytotic uptake which was underlined by a co-localization with LysoTracker-Red® dye as well as pre-incubation with Cytochalasin D. In conclusion, a primitive immune response with efficient phagocytosis was responsible for the anti¬bacterial capacity of differentiated EBs.
    Stem cells and development 02/2013; · 4.15 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: The interaction between surfactant protein-A (SP-A) and TLR4 is important for host defense. We have recently identified an SPA4 peptide region from the interface of SP-A-TLR4 complex. Here, we studied the involvement of the SPA4 peptide region in SP-A-TLR4 interaction using a two-hybrid system, and biological effects of SPA4 peptide in cell systems and a mouse model. HEK293 cells were transfected with plasmid DNAs encoding SP-A or a SP-A-mutant lacking SPA4 peptide region and TLR4. Luciferase activity was measured as the end-point of SP-A-TLR4 interaction. NF-κB activity was also assessed simultaneously. Next, the dendritic cells or mice were challenged with Escherichia coli-derived LPS and treated with SPA4 peptide. Endotoxic shock-like symptoms and inflammatory parameters (TNF-α, NF-κB, leukocyte influx) were assessed. Our results reveal that the SPA4 peptide region contributes to the SP-A-TLR4 interaction and inhibits the LPS-induced NF-κB activity and TNF-α. We also observed that the SPA4 peptide inhibits LPS-induced expression of TNF-α, nuclear localization of NF-κB-p65 and cell influx, and alleviates the endotoxic shock-like symptoms in a mouse model. Our results suggest that the anti-inflammatory activity of the SPA4 peptide through its binding to TLR4 can be of therapeutic benefit.
    Innate Immunity 03/2013; · 2.46 Impact Factor


Available from
May 31, 2014